secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0000950170-23-020073
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics Q1 net loss $2.7M; ALS data halt progression; Dr. Reddy's deal
--------------------------------------------------------------------------------

- Net loss of $2.7M ($0.28 per share) for Q1 2023 vs $1.7M loss in Q1 2022.
- Cash and cash equivalents $16.3M as of March 31, 2023.
- Positive proof-of-concept data for COYA 302 in ALS: halted disease progression at 24 weeks, minimal decline at 48 weeks.
- Entered worldwide agreement with Dr. Reddy's: in-licensed abatacept biosimilar for COYA 302, out-licensed COYA 301 to Dr. Reddy's for certain territories.
- Appointed Arun Swaminathan, Ph.D. as Chief Business Officer; plans to file IND for phase 2 ALS trial in H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000095017023020073/0000950170-23-020073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000095017023020073/coya-20230510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer